Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807677 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00807677 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 31 participants.
The verdict
NCT00807677, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies.
Interventions
- DRUG TAK-901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-03 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807677
The ClinicalTrials.gov registry entry for NCT00807677 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAK-901 is the first listed.
NCT00807677 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00807677 about?
NCT00807677 is a clinical study titled "A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies". The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies.
What is the current status of trial NCT00807677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-03. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00807677?
The interventions under investigation include: TAK-901 (DRUG).
Who is sponsoring clinical trial NCT00807677?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.